Neurological manifestations of lysosomal storage diseases
- PMID: 39525762
- PMCID: PMC11543150
- DOI: 10.1097/MS9.0000000000002611
Neurological manifestations of lysosomal storage diseases
Abstract
Lysosomal storage diseases (LSDs) encompass a group of rare inherited metabolic disorders characterized by the accumulation of undegraded substrates within lysosomes, leading to multisystemic manifestations, including profound neurological involvement. This article provides a concise overview of the neurological manifestations of LSDs, with a focus on central nervous system (CNS) involvement and treatment strategies. While the paper intricacies of each LSD subtype and its associated CNS manifestations, it aims to provide a summary of the essential findings and implications. The neurological manifestations of LSDs encompass a spectrum of symptoms, including cognitive impairment, motor dysfunction, seizures, and sensory deficits, which significantly impact patients' quality of life and pose therapeutic challenges. Current treatment strategies primarily aim to alleviate symptoms and slow disease progression, with limited success in reversing established neurological damage. Enzyme replacement therapy, substrate reduction therapy, and emerging gene therapies hold promise for addressing CNS involvement in LSDs. However, challenges such as blood-brain barrier penetration and long-term efficacy remain. In addition to discussing treatment modalities, this article highlights the importance of early diagnosis, multidisciplinary care, and patient advocacy in optimizing outcomes for individuals affected by LSDs. Ethical considerations are also addressed, including equitable access to emerging treatments and integrating personalized medicine approaches. Overall, this article underscores the complex interplay between genetics, neuroscience, and clinical care in understanding and managing the neurological manifestations of LSDs while emphasizing the need for continued research and collaboration to advance therapeutic interventions and improve patient outcomes.
Keywords: CNS involvement; lysosomal storage diseases; multidisciplinary care; neurological manifestations; treatment strategies.
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The views and opinions expressed in this paper are solely those of the authors and do not necessarily reflect any institution or organization’s official policy or position. The authors declare no conflicts of interest or financial disclosures related to this research.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
References
-
- Giugliani R, Vairo F, Kubaski F, et al. . Neurological manifestations of lysosomal disorders and emerging therapies targeting the CNS. Lancet Child Adolesc Health 2018;2:56–68. - PubMed
-
- Sedel F, Turpin JC, Baumann N. Présentations neurologiques des maladies lysosomales chez l’adulte [Neurological presentations of lysosomal diseases in adult patients]. Rev Neurol (Paris) 2007;163:919–929. - PubMed
-
- van Gool R, Tucker-Bartley A, Yang E, et al. . Targeting neurological abnormalities in lysosomal storage diseases. Trends Pharmacol Sci 2022;43:495–509. - PubMed
-
- Crawley AC, Walkley SU. Developmental analysis of CNS pathology in the lysosomal storage disease alpha-mannosidosis. J Neuropathol Exp Neurol 2007;66:687–697. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources